NURTEC ODT 75 mg
RIMEGEPANT (RIMEGEPANT SULFATE) 75 MG · DIN 02543605 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is NURTEC ODT?
NURTEC ODT 75 mg contains RIMEGEPANT (RIMEGEPANT SULFATE) 75 MG. It is listed in the Health Canada Drug Product Database under DIN 02543605, held by PFIZER CANADA ULC, supplied as Tablet (Orally Disintegrating) for Oral administration. Health Canada currently lists it as marketed, status dated 25-Mar-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NURTEC ODT used for?
Acute treatment of migraine with or without aura in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02543605 |
|---|---|
| Brand name | NURTEC ODT |
| Generic / active ingredient | RIMEGEPANT (RIMEGEPANT SULFATE) 75 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 75 mg |
| Dosage form | Tablet (Orally Disintegrating) |
| Route of administration | Oral |
| Schedule | PRESCRIPTION |
| ATC code | N02CD06 RIMEGEPANT |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 25-Mar-2024 |
How is it administered?
Recommended dose: 75 mg as needed, once daily. Maximum 75 mg/day. Safety of >15 doses in 30 days not established. Place on or under tongue; disintegrates in saliva. Take with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (Section 11 header present but content missing), though instructions state to take immediately after opening blister and not store outside blister.
How is it supplied?
Blister packs of 2, 8, or 16 (2x8) orally disintegrating tablets in a carton.
Contraindications
Hypersensitivity to rimegepant or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Hypersensitivity reactions (dyspnea, rash) can occur days after administration. Discontinue immediately if reaction occurs. Avoid in severe hepatic or end-stage renal impairment.
Who else supplies RIMEGEPANT worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RIMEGEPANT appears in 23 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.